The overall objective of the SysMedPD project is to further explore and identify novel drug candidates capable of slowing down the progression of neurodegeneration in the subset of Parkinson’s Disease (PD) patients with overt mitochondrial dysfunction.
“Avicenna – A Strategy for in silico Clinical Trials” was a Coordination and Support Action funded by the European Commission. Avicenna was tasked with writing a Roadmap to define the strategy for developing In Silico Clinical Trials.
The main goal of the CombiMS project is to identify a new method for drug discovery based on systems biology and to validate this approach by identifying novel combination therapies for Multiple Sclerosis.
The main goal of the PRIAT Project consists in the development and use of HLA peptidome analysis for the study of interpatient and intrapatient variations in the immunopeptidome in response to antibody treatment.
The PerMed consortium has 27 international partners representing key decision makers in research and research policy, industry, healthcare and patient organisations. The aim is to develop a Strategic Research and Innovation Agenda (SRIA) to foster research and implementaion of suitable Personalized Medicine (PM) approaches in Europe and beyond.
The Coordinating Action Systems Medicine (CASyM) will assess the basis for a European Systems Medicine paradigm and will assist the medical community in creating the foundation for a new perspective by focusing on an approach based on personalized, predictive, preventive and participatory (4P medicine).